Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder

Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder

US Patent 7008637 · Granted Mar 7, 2006

Estimated economic value: $340,478,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Microrna-based method for assessing the prognosis of a prostate cancer patient2019
Therapeutic formulation for administering tolterodine with controlled release2004
Therapeutic formulation for administering tolterodine with controlled release2004
Therapeutic formulation for administering tolterodine with controlled release2004
Transdermally administered acetylcysteine as mucolytic agent2003
Transdermally administered acetylcysteine as mucolytic agent2003
Transdermally administered tolterodine as anti-muscarinic agent for the treatmen2003
Transdermally administered tolterodine as anti-muscarinic agent for the treatmen2003
Transdermally administered tolterodine as anti-muscarinic agent for the treatmen2003
Transdermally administered dextromethorphan as antitussive agent2002
Transdermally administered dextromethorphan as antitussive agent2002
Test patch and its use for demonstrating contact allergy1997